

ASX Announcement | 3 June 2022
Visioneering Technologies (ASX:VTI)

Results of Annual Meeting of Stockholders

Atlanta, Georgia, USA Thursday, 2 June 2022 (Sydney Friday, 3 June 2022): US-based medical device company and producer of the NaturalVue® Multifocal 1 Day Contact Lenses, **Visioneering Technologies, Inc (ASX: VTI)** ('Visioneering', 'VTI' or 'the Company') announces the results of its 2022 Annual Meeting of Stockholders held today. The results of the meeting are set out in the table below in accordance with ASX Listing Rule 3.13.2.

Resolutions were decided by way of a poll, with Resolutions 1, 2 and 3 being passed. Resolution 4 was a Special Resolution and did not receive the requisite percentage of votes cast to pass, therefore it will not come into effect.

Holder Voting Summary

Shares Issued and Outstanding: 24,030,560
 Shares Voted: 13,492,849
 Shares Voted (%): 56.15%

The aggregate number of securities for which proxy votes were received prior to the meeting and for each resolution were the same as the aggregate number of securities voted on the poll and for each resolution for each poll.
 All resolutions were decided by a poll.

Resolution	Vote Type	Voted #	Voted %	Result
Item 1. Election of Class II Director – Dr. David J. Mazzo	For Withheld	13,033,608 380,905	97.16% 2.84%	Carried
Item 2. Grant of Shares to Dr. Stephen Snowdy, former CEO, in lieu of earned but unpaid short-term cash incentive for FY21	For Against Abstain	9,194,470 4,256,322 7,243	68.32% 31.63% 0.05%	Carried
Item 3. Approval of increase in shares under 2017 Equity Incentive Plan and other amendments	For Against Abstain	12,522,184 399,363 1,360	96.90% 3.09% 0.01%	Carried
Item 4. Approval of 10% Placement Facility	For Against Abstain	6,557,536 6,927,453 7,860	48.60% 51.34% 0.06%	Not Carried

Ends.

This release was authorized by the COO & CFO, Brian Lane.

Company	Investor and media relations
Brian Lane Chief Operating & Financial Officer Vioneering Technologies, Inc. Email: blane@vtivision.com	Haley Chartres H^CK Tel: +61 423 139 163 Email: haley@hck.digital

About Vioneering Technologies

Vioneering Technologies Inc. (ASX:VTI) is an innovative eye care company committed to redefining vision. A pioneer in myopia management, VTI merges advanced engineering with a relentless drive to achieve superior results for patients and practitioners. VTI's flagship product is the NaturalVue® (etafilcon A) Multifocal 1-Day Contact Lens, an extended depth of focus lens that is one of the most significant innovations in the eye care industry in more than 20 years. For more information, please visit www.vtivision.com.

Foreign ownership restrictions

VTI's CHES Depositary Interests (**CDIs**) are issued in reliance on the exemption from registration contained in Regulation S of the US Securities Act of 1933 (**Securities Act**) for offers which are made outside the US. Accordingly, the CDIs have not been, and will not be, registered under the Securities Act or the laws of any state or other jurisdiction in the US. As a result of relying on the Regulation S exemption, the CDIs are 'restricted securities' under Rule 144 of the Securities Act. This means that you are unable to sell the CDIs into the US or to a US person for the foreseeable future except in very limited circumstances after the expiration of a restricted period, unless the re-sale of the CDIs is registered under the Securities Act or an exemption is available. To enforce the above transfer restrictions, all CDIs issued bear a 'FOR US' designation on the Australian Securities Exchange (**ASX**). This designation restricts any CDIs from being sold on ASX to US persons. However, you are still able to freely transfer your CDIs on ASX to any person other than a US person. In addition, hedging transactions with regard to the CDIs may only be conducted in accordance with the Securities Act.

Forward-Looking Statements

This announcement contains or may contain forward-looking statements that are based on management's beliefs, assumptions, plans and expectations and on information currently available to management.

All statements that address operating performance, events or developments that we expect or anticipate will occur in the future are forward-looking statements. These include, without limitation, U.S. commercial market acceptance and U.S. sales of our product, as well as our expectations with respect to our ability to develop and commercialize new products.

Given the current uncertainties regarding the on-going impact of COVID-19 on the trading conditions impacting VTI, the financial markets and the health services world-wide, there can be no assurance that future developments will be in accordance with VTI's expectations or that the effect of future developments on VTI will be those anticipated.

Management believes that these forward-looking statements are reasonable when made. You should not place undue reliance on forward-looking statements because they speak only as of the date when made. VTI does not assume any obligation to publicly update or revise any forward-looking statements, whether as a result of new information, future events or otherwise. VTI may not actually achieve the plans, projections or expectations disclosed in forward-looking statements. Actual results,

developments or events could differ materially from those disclosed in the forward-looking statements.

VTI-IR-ASX63